Our take on the latest news and views on data.

Relevant company news, articles, podcasts, and blog posts.

Recent Posts

Industry Trends

Clinical Trial Trends

Disease Area Trends

Recent Tweets

$IVBIY Innovent announces approval of IBI311 (IGF-1R antibody) NDA by China's NMPA for Thyroid Eye Disease.

More Info: https://pryzm.ozmosi.com/product/26143 $XBI $IBB $XPH $PPH

Telix finishes a proof-of-concept study for TLX592 Targeted Alpha Therapy in treating prostate cancer.

More Info: https://pryzm.ozmosi.com/product/24326 $XBI $IBB $XPH $PPH

Avalyn showcases clinical data on AP01 for Pulmonary Fibrosis, featuring long-term effectiveness and imaging biomarker results, at ATS 2024.

More Info: https://pryzm.ozmosi.com/product/32013 $XBI $IBB $XPH $PPH

$LRMR Larimar Therapeutics reports FDA lifts partial clinical hold for Nomlabofusp program in Friedreich's Ataxia.

More Info: https://pryzm.ozmosi.com/product/21527 $XBI $IBB $XPH $PPH

Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

600 Warren Ave,
Spring Lake, NJ 07762